

CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND
INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

As a result of these procedures, the disease specific marker having a sequence identified as SEQ ID NO: 1 was found. This marker is characterized as a C3f fragment from the complement system having a molecular weight of about 1793 daltons. The characteristic profile of the marker is set forth in Figure 2. As easily deduced from the data set forth in Figure 1, this marker is indicative of an individual suffering from congestive heart failure.

IN THE CLAIMS:

1. A biopolymer marker having a sequence identified as SEQ ID NO: 1 useful in indicating at least one particular disease state.

17. The diagnostic assay kit of claim 10, wherein said marker includes the sequence identified as SEQ ID NO: 1 and said biochemical material is at least one monoclonal antibody specific therefore.

18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker including the sequence identified as

SEQ ID NO: 1 or an analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal antibody specific therefore.

29. Polyclonal antibodies produced against the marker having a sequence identified as SEQ ID NO: 1 in at least one animal host.

30. An antibody that specifically binds a biopolymer including the marker sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

33. A process for identifying therapeutic avenues related to a disease state comprising:
conducting an analysis as provided by the kit of claim 18; and
interacting with a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof;
whereby therapeutic avenues are developed.

34. The process for identifying therapeutic avenues related to a disease state in